Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


Invasion ( 2953 / 1502 /
481
/
970
)
migration ( 2359 / 1195 /
383
/
781
)
colony formation ( 399 / 205 /
54
/
140
)
cell cycle ( 248 / 130 /
44
/
74
)
Proliferation ( 3262 / 1651 /
533
/
1078
)
cell cycle progression ( 167 / 85 /
40
/
42
)
Cell growth ( 686 / 347 /
98
/
241
)
Senescence ( 61 / 34 /
19
/
8
)
cell cycle arrest ( 491 / 249 /
214
/
28
)
MTX resistance ( 3 / 2 /
0
/
1
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Metastasis ( 953 / 485 /
183
/
285
)
AKT signaling ( 207 / 105 /
37
/
65
)
cisplatin resistance ( 232 / 117 /
36
/
79
)
Autophagy ( 303 / 152 /
70
/
81
)
survival ( 132 / 68 /
23
/
41
)
Apoptosis ( 1428 / 728 /
458
/
242
)
cell viability ( 252 / 130 /
32
/
90
)
5fluorouracil resistance ( 74 / 46 /
12
/
16
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
Lung metastasis ( 49 / 26 /
11
/
12
)
DNA repair ( 47 / 24 /
16
/
7
)
TGF-beta signaling ( 362 / 204 /
78
/
80
)
motility ( 173 / 89 /
27
/
57
)
EMT ( 679 / 346 /
145
/
188
)
stemness ( 189 / 95 /
44
/
50
)
BMP signaling ( 108 / 63 /
13
/
32
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
JAK/STAT signaling ( 84 / 43 /
22
/
19
)
Angiogenesis ( 258 / 134 /
40
/
84
)
growth ( 222 / 131 /
26
/
65
)
tumor-initiating properties ( 9 / 6 /
0
/
3
)
tumor growth ( 634 / 320 /
106
/
208
)
Chemoresistance ( 260 / 131 /
44
/
85
)
Paclitaxel resistance ( 47 / 24 /
10
/
13
)
beta-catenin signaling ( 45 / 23 /
11
/
11
)
Brain metastasis ( 2 / 1 /
0
/
1
)
docetaxel resistance ( 25 / 14 /
7
/
4
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
adhesion ( 47 / 26 /
7
/
14
)
NF-kB signaling ( 115 / 59 /
30
/
26
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Oxaliplatin resistance ( 23 / 12 /
5
/
6
)
Anoikis ( 22 / 12 /
4
/
6
)
MET ( 18 / 10 /
8
/
0
)
differentiation ( 95 / 48 /
31
/
16
)
Tamoxifen resistance ( 11 / 6 /
5
/
0
)
Radioresistance ( 103 / 53 /
22
/
28
)
inflammation ( 55 / 28 /
7
/
20
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Sorafenib resistance ( 26 / 13 /
6
/
7
)
tumor progression ( 82 / 42 /
24
/
16
)
aerobic glycolysis ( 51 / 26 /
8
/
17
)
ER stress ( 28 / 15 /
0
/
13
)
Oxaliplatin ( 2 / 1 /
1
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
etoposide ( 7 / 4 /
2
/
1
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
doxorubicin resistance ( 57 / 29 /
8
/
20
)
multidrug resistance ( 20 / 11 /
4
/
5
)
ERK pathway (MAPK pathway) ( 113 / 57 /
18
/
38
)
Liver metastasis ( 22 / 13 /
3
/
6
)
scattering ( 1 / 1 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
Temozolomide (TMZ) resistance ( 26 / 13 /
5
/
8
)
WNT signaling ( 180 / 91 /
48
/
41
)
cancer progression ( 16 / 9 /
5
/
2
)
PI3K signaling ( 79 / 40 /
12
/
27
)
inflammatory monocyte recruitment ( 4 / 3 /
0
/
1
)
erythropoiesis ( 3 / 3 /
0
/
0
)
NK cell cytotoxicity ( 6 / 4 /
0
/
2
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
Castrate Resistance ( 23 / 14 /
8
/
1
)
Bone metastasis ( 18 / 11 /
1
/
6
)
anchorage-independent growth ( 29 / 15 /
9
/
5
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
macrophage attraction ( 1 / 1 /
0
/
0
)
tumor-stroma interactions ( 3 / 2 /
1
/
0
)
Imatinib resistance ( 6 / 5 /
0
/
1
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
disease-free survival ( 3 / 2 /
0
/
1
)
epirubicin resistance ( 3 / 2 /
1
/
0
)
Transformation ( 15 / 12 /
2
/
1
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
NOTCH signaling ( 51 / 26 /
15
/
10
)
gefitinib resistance ( 22 / 12 /
2
/
8
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
poor prognosis ( 46 / 26 /
17
/
3
)
unfolded protein response ( 5 / 4 /
0
/
1
)
P38 signaling ( 29 / 15 /
10
/
4
)
Vorinostat Resistance ( 6 / 4 /
2
/
0
)
Osteolysis ( 5 / 3 /
0
/
2
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
Tumorigenesis ( 39 / 20 /
6
/
13
)
Adriamycin (Adr) resistance ( 22 / 12 /
3
/
7
)
lipogenesis ( 23 / 12 /
0
/
11
)
mTOR signaling ( 76 / 38 /
8
/
30
)
cytotoxicity ( 2 / 1 /
1
/
0
)
gluconeogenesis ( 4 / 2 /
0
/
2
)
chondrogenesis ( 1 / 1 /
0
/
0
)
Lapatinib resistance ( 2 / 1 /
0
/
1
)
Neratinib resistance ( 2 / 1 /
0
/
1
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
0
)
Response to oxidative stress ( 5 / 5 /
0
/
0
)
T cell activation ( 3 / 2 /
1
/
0
)
gemcitabine resistance ( 34 / 17 /
6
/
11
)
genomic instability ( 2 / 1 /
1
/
0
)
glycolysis ( 10 / 10 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
Taxanes (paclitaxel and docetaxel) resistance ( 8 / 7 /
0
/
1
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
Hippo signaling pathway ( 164 / 82 /
65
/
17
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
0
)
BRAFi resistance ( 2 / 1 /
0
/
1
)
MEKi resistance ( 2 / 1 /
0
/
1
)
immunoevasion ( 16 / 8 /
3
/
5
)
MAPK/JNK Signaling Pathway ( 8 / 4 /
4
/
0
)
Hypoxic response ( 8 / 5 /
3
/
0
)
carboplatin resistance ( 2 / 1 /
0
/
1
)
Trastuzumab resistance ( 4 / 2 /
1
/
1
)
fibrosis ( 12 / 6 /
2
/
4
)
TRAIL resistance ( 2 / 1 /
0
/
1
)
Rapamycin resistance ( 2 / 1 /
0
/
1
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)